I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology WCLC 2024
Roche and Genentech at

WCLC 2024

September 07 - September 10
San Diego, USA
wclc.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Sep 10 / Roche and Genentech
LCMC3: Long-term disease-free and overall survival and their association with ctDNA after neoadjuvant atezolizumab for NSCLC
LCMC3 is a Phase II trial that evaluated the safety and efficacy of neoadjuvant atezolizumab followed by optional adjuvant atezolizumab and/or chemo in patients with early-stage, resectable NSCLC. This presentation reports the final disease-free survival and overall survival results and their association with ctDNA status and clearance in the LCMC3 study.
Oncology Lung Cancer WCLC-2024

Sign up or login to unlock the full suite of MEDICALLY features
Sep 9 / Roche and Genentech
Divarasib single-agent long-term follow-up and atezolizumab combination treatment in patients with KRAS G12C-positive NSCLC
Long-term follow-up phase 1 data of divarasib single-agent, and safety and efficacy of divarasib in combination with atezolizumab, in patients with KRAS G12C-positive NSCLC.
Oncology Lung Cancer WCLC-2024

Sign up or login to unlock the full suite of MEDICALLY features
Sep 9 / Roche and Genentech
Divarasib versus Adagrasib or Sotorasib in Pretreated KRAS G12C+ Advanced or Metastatic Non-Small Cell lung Cancer (NSCLC)
Trial-in-progress poster presenting the study design and objectives of the Phase III Krascendo 1 trial of divarasib versus adagrasib or sotorasib in advanced/metastatic KRAS G12C+ NSCLC.
Oncology Lung Cancer WCLC-2024
07:00 PM
Duration 2hrs San Diego, USA
An evidence-driven approach to optimising clinical, operational, and economic value in the lung cancer care pathway
Margarita Majem, Ivana Gabriela Sullivan, Alfons Torrego, Jordi Surrallés, John Purdy, Marina Ascorbe Carmona, Harry Dunsford, Matthias Wubs
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:00 PM
Duration 2hrs San Diego, USA
Exploring circulating tumor antigens as a faster and lower cost alternative to circulating tumor DNA in IMpower150
Namrata S Patil
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:57 PM
Duration 10mins 20A
IMpower010 5-y subgroup analysis and relapse patterns: Phase 3 study of atezolizumab vs BSC in stage II-IIIA NSCLC
Felip E, Wakelee HA, Vallieres E, Martinez-Marti A, Goloborodko O, Zhou C, Rittmeyer A, Chella A, Reck M, Csoszi T, Bondarenko I, Kenmotsu H, Shutte W, Ding B, Zhu C, Ballinger M, Bennett E, Gitlitz BJ, Altorki N
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:15 AM
Duration 90mins San Diego, USA
LCMC3: Clinical Utility of SUVmax on Preoperative 18F-FDG PET-CT in Resectable NSCLC Treated with Neoadjuvant Atezolizumab
B Merritt, D Carbone, E Toloza, J Lee, A Patterson, V Rusch, B Johnson, P Bunn, K Schulze, A Nicholas, A Johnson, D Owen
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 AM
Duration 2hrs San Diego, USA
Divarasib versus Adagrasib or Sotorasib in Pretreated KRAS G12C+ Advanced or Metastatic Non-Small Cell lung Cancer (NSCLC)
Shirish M. Gadgeel, Uyi Osaghae, Ahmadur Rahman, Tharu M. Fernando, Mark T. Lin, Kalpesh Koli, Christoph Meyenberg, Michael Mathisen, Ferdinandos Skoulidis
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:30 PM
Duration 45mins 20A
ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)
Hidehito Horinouchi, Benjamin J. Solomon, Yi-Long Wu, Fabrice Barlesi, Makoto Nishio, Jin Seok Ahn, Dae Ho Lee, Jong-Seok Lee, Wenzhao Zhong, Maximilian Hochmair, Igor Bondarenko, David Planchard, Achim Rittmeyer, Beiying Ding, Thorsten Ruf, Leah Adler, Astrid Scalori, Rafal Dziadziuszko
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 45mins 20D
Divarasib single-agent long-term follow-up and atezolizumab combination treatment in patients with KRAS G12C-positive NSCLC
Sacher A, Wilson H. Miller Jr., Luis Paz-Ares, Myung-Ju Ahn, Manish R. Patel, Rafal Dziadziuszko, Armando Santoro, Jia Luo, Ben Markman, Pierre Freres, Marloes Van Dongen, Jayesh Desai, Samantha Bowyer, Andres Cervantes, Josiane Mourão Dias, Alejandro Falcon, Matthew G. Krebs, Scott Laurie, Hans Prenen, Ruth Perets, Erminia Massarelli, Se Hyun Kim, Maria De Miguel, Sanjeev Deva, Elena Garralda, Laura Medina, João Daniel Guedes, Salvatore Siena, Tormod Guren, Eugenio Fernandez, Loes Latten Jansen, Rita De Cassia Costamilan, Yoonha Choi, Sandhya Mandlekar, Mark T. Lin, Kenneth K. Yau, Julie Chang, Stephanie Royer-Joo, Tomi Jun, Neekesh V. Dharia, Jennifer L. Schutzman, Patricia Lorusso
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:35 PM
Duration 75mins 20A
LCMC3: Long-term disease-free and overall survival and their association with ctDNA after neoadjuvant atezolizumab for NSCLC
D H. Owen, J E. Chaft, E B. Haura, E Toloza, S N. Waqar, G. A Patterson, D Finley, J Blasberg, D Raz, R Salgia, J M. Lee, P Bunn, I Wistuba, D J. Kwiatowski, F Hirsch, A Gopalakrishnan, A Batra, E Brandao, J Grindheim, A Nicholas, A Johnson, K Schulze, E Shum, M Nagasaka, J Gainor, C J. McNamee, B E. Johnson, M G. Kris, V W. Rusch, D P. Carbone
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.